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Lipids have been long recognized to play a pivotal role in atherosclerosis. Inflammation 46 
has also been acknowledged as a key biological process in this disorder1.  Importantly, 47 
dyslipidemia and inflammation are closely intertwined in their contribution to 48 
atherosclerosis and cardiovascular risk2. For example, lipid-lowering drugs that 49 
effectively decrease cardiovascular (CV) events also exhibit anti-inflammatory effects3. 50 
On the other hand, some of the anti-inflammatory effects reported for statins, and also 51 
for aspirin and renin-angiotensin modulators3-5 may result from. lipid-lowering, 52 
antithrombotic or anti-proliferative effects, as well as improved endothelial function. In 53 
addition, observational studies have suggested beneficial effects of anti-inflammatory 54 
drugs used for other indications in terms of reducing CV risk6. However, until recently, 55 
direct evidence on the efficacy of anti-inflammatory strategies to reduce CV events in 56 
humans was lacking. Thus, there was a need for a definitive study to specifically 57 
address the specific anti-inflammatory effects on CV events. 58 
The recent Canakinumab Antiinflammatory Thrombosis Outcomes Study 59 
(CANTOS) has addressed this question. This trial investigated high-risk patients after 60 
acute coronary syndromes (ACS) on statin therapy and increased inflammatory burden 61 
(CRP levels >2 mmol/L). It demonstrated that CV outcome was improved after 62 
inhibition of interleukin-1く (IL-1く) without affecting lipid levels7. These results 63 
introduce a new paradigm for the treatment of human atherosclerosis. In this Consensus 64 
Paper, we highlight the role of inflammation and dyslipidemia in atherosclerosis and 65 
aim to outline the new issues and challenges that are brought up by the interplay 66 
between these two CV risk factors in cardiovascular prevention. 67 
 5 
 68 
LIPID-INDUCED INFLAMMATORY RESPONSES (Figure 1) 69 
A key trigger of atherosclerosis is subintimal retention of low-density lipoproteins 70 
(LDL) at regions of complex flow or low shear stress.8 Modified LDL (mLDL) species 71 
are strong inducers of inflammation and have a marked impact on atherosclerosis9. They 72 
alter vascular physiology by activating pattern recognition receptors, such as toll-like 73 
receptors (TLRs), which trigger proinflammatory signals and reactive oxygen species 10 74 
and promote matrix degradation11. These TLRs will prime the Nod-like receptor 75 
protein 3 (NLRP3) inflammasome for activation by cholesterol crystals leading to IL-76 
1く activation.12 Pathway activation leads to the increased release of cytokines 13 and77 
activate the endothelium by increasing the expression of adhesion molecules and 78 
chemokines, costimulatory molecules, and pro-inflammatory transcription factors, such 79 
as CD40 and nuclear factor-B (NF-せB)14-16, and trained immunity17  that promote the 80 
recruitment of inflammatory cells into the vascular wall. Macrophages are of key 81 
relevance 18 since they can scavenge oxidized LDL leading to their transformation into 82 
pro-atherogenic foam cells1, 6, 19.  83 
Adaptive immune responses play a key role in atherogenesis. Activated T 84 
lymphocytes are present in both peripheral blood and coronary plaques in patients with 85 
ACS 1, 20, and especially Th1-derived cytokines such as TNF(tumour necrosis factor 86 
), interferon-gamma and interleukin-12 are associated with atherosclerosis. Although 87 
the notion of immunomodulatory effects of lipid-lowering agents emerged from both 88 
experimental and clinical studies21, 22, the causal relation between lipids and immunity 89 
with regard to atherogenesis remains incompletely understood.  90 
 91 
ANTI-INFLAMMATORY EFFECTS OF LIPID-LOWERING THERAPIES 92 
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There is overwhelming evidence showing that statins have anti-inflammatory and 93 
immunomodulatory effects. They decrease the activity of the transcription factor NF-94 
せB3, with subsequent diminution in the expression of adhesion molecules, cytokines and 95 
MMPs, interfering also with the arachidonic/cyclooxygenase (COX) pathway23a-23b. 96 
Also, they reduce plasma levels of inflammatory markers such as C-reactive protein 97 
(CRP)24. Although most evidence has been obtained with statins, other lipid-lowering 98 
approaches show similar inhibitory effects on inflammation. For instance, ezetimibe and 99 
fibrates also inhibit the NF-せB pathway and decrease CRP levels25-28. Similarly, low fat 100 
diet reduces CRP levels29 and Mediterranean diet also decreases CD40 expression on 101 
monocytes and plasma levels of cell adhesion molecules and cytokines30. Accordingly, 102 
lipid-lowering has been shown to decrease the incidence of cardiovascular events 103 
independently of the employed therapy31. 104 
Recently, another class of lipid-lowering drugs, Proprotein convertase 105 
subtilisin/kexin type 9 (PCSK9) inhibitors, have been demonstrated to reduce the of 106 
cardiovascular events32, 33. Although PCSK9 inhibitors do not decrease CRP plasma 107 
levels, 34 35 they reduce Lipoprotein (a) levels -a molecule that promotes inflammation, 108 
oxidative stress, and coagulation36- and decrease monocyte activation and 109 
transmigration in patients with familial hypercholesterolemia34. Moreover, antibody-110 
based PCSK9 inhibition in atherosclerotic mice diminished plaque macrophage and 111 
necrotic core content 37.. Conversely, up-regulation of hepatic LDL receptors (LDLR) 112 
by PCSK9 inhibition results in increased lipopolysaccharide clearance, a decreased 113 
inflammatory response, and improved survival following sepsis in mice,38 while patients 114 
with PCSK9 loss-of-function variants exhibit improved clinical outcomes during septic 115 
shock39. Likewise, PCSK9 expression can be experimentally induced by pro-116 
inflammatory molecules, such as Lipopolysaccharide, TNFg, and hepatocyte nuclear 117 
factor-1g 40-41.  118 
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Also, PCSK9 modulates LDLR expression in macrophages, 46 47 promoting the 119 
expression of pro-inflammatory markers, and inhibiting anti-inflammatory molecules47. 120 
In humans, plasma PCSK9 concentrations increase in sepsis48,  trauma49, and in acute 121 
coronary syndromes, and they are positively associated with hsCRP50, white blood cell 122 
count, and fibrinogen in coronary patients51. In conclusion, this evidence confirms that 123 
all LDL-c-lowering therapies employed to date decrease inflammation.  124 
 125 
ANTI-INFLAMMATORY THERAPY AND CARDIOVASCULAR RISK 126 
Inflammatory cytokines such as IL-152 and TNF53 have been detected in human 127 
coronary atherosclerosis. Observational studies have revealed an association of different 128 
anti-inflammatory treatments, when used for their indications, with reduced 129 
cardiovascular risk,  providing support for the concept of anti-inflammation in 130 
cardiovascular prevention6. It is the case of anti-TNF therapy in rheumatoid arthritis54, 55 131 
and anti-leukotrienes in asthmatics56 that apparently decreased the incidence of 132 
cardiovascular events. 133 
On the other hand, other anti-inflammatory drugs failed to decrease the 134 
cardiovascular risk, as was observed for steroids in patients with unstable angina57. 135 
With the exception of aspirin, non-steroidal anti-inflammatory (NSAIDs) drugs, 136 
especially COX-2 inhibitors, have in general increased cardiovascular risk58, 59, 60, 137 
indicating that this class of anti-inflammatory drugs should be limited to patients 138 
without other alternatives59. Interestingly, the PRECISION (Prospective Randomized 139 
Evaluation of Celecoxib Integrated Safety versus Ibuprofen or Naproxen) trial showed 140 
non-inferiority of celecoxib versus ibuprofen and naproxen regarding cardiovascular 141 
events61 highlighting some hypertensive effects of these drugs. Interestingly, these 142 
effects were minimal for celecoxib. 143 
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The recent CANTOS trial sets a new paradigm in the relationship of 144 
inflammation with atherosclerosis and lipids7. In this randomized, double-blind trial, 145 
10,061 high-risk patients with a previous myocardial infarction, majority using 146 
moderate to high intensity statin therapy and hsCRP>2 mg/L received canakinumab, a 147 
monoclonal antibody that blocks IL1, or placebo. After a median follow-up of 3.7 148 
years there was a ~15% decrease in the incidence of the primary end point composed of 149 
nonfatal myocardial infarction, nonfatal stroke with the highest dose investigated. 150 
Interestingly, an even higher risk reduction of ~27% was observed in patients 151 
characterized by above median reduction of CRP following canakinumab administration 152 
(ESC presentation Ridker). While there was an increase in the incidence of fatal 153 
infections, neutropenia or thrombocytopenia in patients on canakinumab, there were 154 
also non-CV benefits, comprising a reduction in the incidence of lung cancer, cancer 155 
mortality, arthritis, and gout 7, 62.  156 
 157 
IMPACT OF THE CANTOS TRIAL ON OUR UNDERSTANDING OF 158 
INTERPLAY BETWEEN LIPIDS AND INFLAMMATION 159 
The results from the CANTOS trial provide a first proof-of-principle about the link 160 
between lipids and inflammation. In this trial, canakinumab did not decrease lipid 161 
levels62. Thus, the CANTOS data excludes the possibility that canakinumab reduces 162 
CV-risk through lipid-dependent mechanisms linked to IL-1. 163 
Patients in the CANTOS trial had mean LDL-C levels of approximately 80 164 
mg/dl and CRP > 2 mg/L. Efforts to further reduce residual CV-risk now have multiple 165 
options. Following the post-hoc analysis in the FOURIER study, Giugliano and 166 
collegues showed that CV-benefit by LDL-c lowering is extended to values even below 167 
20 mg/dl (Giugliano, Fourier, Lancet 2017). Conversely, CANTOS shows that a 168 
persistent CRP reduction following canakinumab may also convey a 25% CV-risk 169 
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reduction (ref Ridker, ESC presentation). Suggested biomarkers to guide personalized 170 
medicine in an effort to further reduce residual burden in high CV-risk patients 171 
comprise absolute LDL-c levels, CRP levels70 or IL-1 genotype71. However, the role 172 
of other inflammatory biomarkers or even imaging strategies (PET/CT ref 173 
Tawakol/Fayad/Rudd; MRI-lipid by Choudhury?) to better select high-responders to 174 
therapeutic moieties targeting either residual lipid or inflammatory pathways remains to 175 
be established72. Last but not least, despite the landmark character of CANTOS, the 176 
high costs of canakinumab preclude its broader use in cardiovascular prevention.  177 
 178 
CONCLUSIONS AND PERSPECTIVES 179 
1) Interplay between lipids and inflammation: The reduction in cardiovascular events 180 
observed with IL1-blockade confirms the link between lipids and inflammation. The 181 
mechanism involves cholesterol crystals (and possibly other lipid species) which 182 
activate non-canonical pathways (TLRs or the NLRP3) to induce maturation of IL-1 183 
which is blocked by canakinumab. 184 
2) Other pro-inflammatory targets appear worth testing. Although IL1 blockade is 185 
today the only anti-inflammatory approach shown to reduce cardiovascular risk in a 186 
randomized clinical trial, the wealth of evidence linking inflammation with 187 
atherosclerosis indicates that other potential targets exist to be evaluated in future trials. 188 
3) Anti-inflammatory therapy is complementary to lipid-lowering and risk factor 189 
control. Canakinumab is not a competitor of lipid-lowering therapies given, among 190 
other reasons, that the large evidence supporting these therapies cannot be compared 191 
with the results of only one clinical trial. 192 
4) CANTOS – a proof-of-principle study for causal role of inflammation in human 193 
atherosclerosis. Although the results of CANTOS trial may be considered a milestone 194 
in cardiovascular medicine, given all the above considerations it is improbable that 195 
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canakinumab is prescribed to patients with cardiovascular risk to improve their 196 
prognosis. Alternatively, an attractive idea would be to systematically and randomly 197 
explore its effect in patients with rheumatologic disorders or in other context of chronic 198 
inflammation using trials with a prespecified cardiovascular endpoint.  199 
5) Would highlight anti-cancer effects.  likely to create impact in the cancer field. 200 
6) Other cheaper tools than antibodies may also do the job of lowering IL1b (e.g. RNA 201 
interference – as in ORION). 202 
7) Anti-inflammatory therapy has a narrow therapeutic window as compared to LDL-C 203 
lowering therapy.  increased infections, sepsis after anti-IL1b therapy, whereas 204 
lowering LDL-C to very very low levels reveals no side effects.  caution with dosing 205 
of anti-inflammatory agents.  206 
. 207 
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FIGURE LEGENDS 537 
Figure 1. Lipid dysregulation triggers inflammatory and immune responses. AP-1: 538 
Activator protein-1; CCR2: Chemokine receptor type-2; COX-2: Cyclooxygenase-2; 539 
DC: Dendritic cells; IKK:  IせB kinase; IL:  Interleukin IL: Interleukin; INFけ: 540 
Interferon-け; JAK-STAT:  Janus kinase and Signal Transducer Activator of 541 
Transcription Proteins; JNK:  Jun kinase; LDL:  low-density lipoprotein; mLDL:  542 
modified LDL; oxLDL:  oxidizwed LDL; Mø: macrophages; MCP-1: Monocyte 543 
chemoattractant protein-1; NF-せB: Nuclear factor-せB; NLR:  NOD-like receptors; 544 
PMN:  Polymorphonuclear; PRR: Pattern recognition receptors; ROS: Rective Oxygen 545 
species; Scav-R: Scavenger receptors; SRA and SRB: Scavenger receptor class A and 546 
B; TGFく: Transforming growth factor-く; TLR:  Toll-like receptor; TNF: Tumor 547 
necrosis factor-; TNF-R: Tumor necrosis factor-receptor; VCAM:  Vascular cell 548 
adhesion molecule. 549 
550 
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